Lanaken

This research investigates the Suicidal Crisis Intervention (SCI), a new short-term treatment designed to reduce suicidality in people who have experienced a suicide attempt or suicidal crisis. The study also aims to explore the effect of SCI on related factors such as hopelessness, defeat, entrapment, and interpersonal needs. The SCI was developed in Flanders to address the lack of specific evidence-based short-term treatments for this high-risk group. The SCI consists of four structured sessions that focus on understanding the suicidal crisis by relating it to the person's life history. It seeks to increase motivation for ongoing specialized care and involves the participation of close relatives to strengthen social support. Key elements of the intervention include a safety plan, person-centered care, and continuity of care, all delivered by care providers within a short time frame. Participants will be monitored for changes in suicidality using the Beck Scale for Suicide Ideation at multiple points: 42, 132, and 222 days after randomization. The study includes assessments of related psychological factors and emphasizes the involvement of relatives. Participants must have internet access and be Dutch-speaking. The total duration and detailed follow-up procedures support evaluating both immediate and longer-term effects of the SCI.

Researchers are evaluating the effects of three different treatments on major adverse kidney events (MAKE) in adults who are unconscious after being resuscitated from out-of-hospital cardiac arrest. This sub-study is part of the larger STEPCARE trial and involves 3,500 participants. The study focuses on kidney-related outcomes, including death within 30 days, need for kidney replacement therapy, and kidney function changes measured by creatinine levels at hospital discharge. The main trial randomly assigns patients to one of three treatments: continuous deep sedation for 36 hours versus minimal sedation; fever control using a feedback-controlled device if body temperature rises above 37.7°C versus fever control without a device; and two blood pressure targets with mean arterial pressure (MAP) set to either ≥65 mmHg or ≥85 mmHg maintained by vasopressors for 36 hours. The feedback-controlled temperature device is set to maintain temperature at 37.5°C when used. Participants will be closely monitored during their hospital stay with data collected prospectively according to the main trial protocol. Researchers will assess major adverse kidney events within 30 days and examine creatinine changes during the hospital stay and within 72 hours after resuscitation. The study aims to understand how these treatments affect kidney outcomes after cardiac arrest, with analyses following a predefined statistical plan.

This research evaluates three different treatment targets for patients who are comatose after being successfully resuscitated from cardiac arrest. The trial involves 3500 participants and focuses on sedation levels, temperature management, and blood pressure goals to understand their effects on survival. The study aims to improve care strategies in the critical period following cardiac arrest by comparing different approaches in a randomized design. Participants are assigned to one of two groups for each treatment target: sedation (deep sedation for 36 hours versus minimal sedation), temperature control (using a feedback-controlled device at 37.5°C versus fever management without a device), and mean arterial pressure (MAP) targets (>85mmHg versus >65mmHg). Vasopressors will be adjusted to maintain the assigned MAP for 36 hours. The interventions are applied during intensive care after the cardiac arrest event. During the study, patients will be monitored closely with follow-ups at 30 days and 6 months after treatment. The primary outcome is survival at 6 months. Researchers will assess mortality and other health indicators during this period to determine the impact of the different treatment approaches. The total participation duration includes the initial treatment phase and these follow-up periods for outcome measurement.